Showing results (501-510 of 673) with videos related to
Sort By:
Pageof 68
Clinical Pharmacology and Therapeutics|May 17, 2012
Operational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT projectJ M Pulley, J C Denny, J F Peterson, et al.JAMA Internal Medicine|April 18, 2022
Assessment of Awake Prone Positioning in Hospitalized Adults With COVID-19: A Nonrandomized Controlled TrialEdward Tang Qian, Cheryl L Gatto, Olga Amusina, et al.Trials|April 23, 2020
In response: Letter on update to the Vitamin C, Thiamine and Steroids in Sepsis (VICTAS) protocolChristopher J Lindsell, Anna McGlothlin, Samuel Nwosu, et al.Iscience|December 13, 2021
Standardized two-step testing of antibody activity in COVID-19 convalescent plasmaPavlo Gilchuk, Isaac Thomsen, Sandra Yoder, et al.Chest|May 3, 2022
Oxygen-Free Days as an Outcome Measure in Clinical Trials of Therapies for COVID-19 and Other Causes of New-Onset HypoxemiaAri Moskowitz, Matthew S Shotwell, Kevin W Gibbs, et al.Journal of Clinical and Translational Science|July 3, 2023
Approaches for enhancing the informativeness and quality of clinical trials: Innovations and principles for implementing multicenter trials from the Trial Innovation NetworkKaren Lane, Marisha E Palm, Eve Marion, et al.Lancet (London, England)|January 15, 2008
Efficacy and safety of a paired sedation and ventilator weaning protocol for mechanically ventilated patients in intensive care (Awakening and Breathing Controlled trial): a randomised controlled trialTimothy D Girard, John P Kress, Barry D Fuchs, et al.Journal of Clinical and Translational Science|September 1, 2023
Decentralized clinical trials in the trial innovation network: Value, strategies, and lessons learnedDaniel F Hanley, Gordon R Bernard, Consuelo H Wilkins, et al.NEJM Evidence|October 22, 2024
Lessons Learned from National Heart, Lung, and Blood Institute Covid-19 Clinical TrialsSonia M Thomas, Robert A Harrington, Clyde W Yancy, et al.Critical Care Medicine|August 28, 2013
A randomized, double-blind, placebo-controlled, Phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulationJean-Louis Vincent, Mayakonda K Ramesh, David Ernest, et al.Pageof 68